{"classes":[{"categories":[{"measurements":[{"comment":"upper limit is not reached","groupId":"OG000","lowerLimit":"4.3","upperLimit":"NA","value":"11.1"},{"comment":"upper limit is not reached","groupId":"OG001","lowerLimit":"5.4","upperLimit":"NA","value":"9.3"},{"groupId":"OG002","lowerLimit":"3.7","upperLimit":"9.3","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"346"},{"groupId":"OG002","value":"344"}],"units":"Participants"}],"description":"Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).","dispersionType":"Inter-Quartile Range","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"OG002","title":"Standard of Care"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.","reportingStatus":"POSTED","timeFrame":"Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).","title":"Duration of Response (DoR), Full Analysis Set","type":"SECONDARY","unitOfMeasure":"Months"}